Ritonavir News and Research

RSS

Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

What is the real-world efficacy of oral antivirals against the SARS-CoV-2 Omicron variant?

A new review commented on a previous study regarding the real-world effectiveness of oral antivirals against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

12 Oct 2022

Observational study explores the real-world efficacy of oral antivirals against the SARS-CoV-2 Omicron variant

A new study reported the real-world efficacy of oral antiviral therapies nirmatrelvir plus ritonavir, and molnupiravir on the SARS-CoV-2 Omicron (B.1.1.529) variant, based on an observational study among coronavirus disease 2019 (COVID-19) patients in Hong Kong.

12 Oct 2022

Molnupiravir and nirmatrelvir-ritonavir treatments are effective in reducing mortality among high-risk COVID-19 patients

A recent study determines the relationship between molnupiravir and nirmatrelvir-ritonavir and all-cause mortality.

12 Oct 2022

Are men or women impacted more by adverse reactions to prescription drug treatments?

Recently, researchers presented an overview of sex-based differences in adverse drug reactions (ADRs) based on epidemiology, technique, and underlying mechanism data.

11 Oct 2022

What is the association of SARS-CoV-2 vaccination with the risk of PASC in patients with SARDs?

Findings of a new study depicted that fully vaccinated patients suffering from systemic autoimmune rheumatic diseases harbor a lower propensity to developing long COVID symptoms compared to SARDs patients who are not fully vaccinated.

11 Oct 2022

Chronic liver disease in COVID-19 patients

A recent study summarizes the clinical outcomes of COVID-19 patients with chronic liver disease.

10 Oct 2022

Acute kidney injury in hospitalized COVID-19 patients

In a new study, researchers examined the phenotypes of acute kidney injury (AKI) in hospitalized coronavirus disease 2019 (COVID-19) patients.

7 Oct 2022

Impaired immune responses not responsible for COVID-19 rebound, findings suggest

Findings from a small study of eight patients published in Clinical Infectious Diseases suggest that COVID-19 rebound is likely not caused by impaired immune responses.

6 Oct 2022

Study finds remdesivir-resistant version of COVID-19 in renal transplant recipients

Recent studies have shown that patients with weakened immune systems—which enables the virus that causes COVID-19 to remain longer in the body, copy itself, and continually change—may enable the development of new, slightly different versions of the virus (variants).

26 Sep 2022

Antibody drugs are not recommended for patients with covid-19, say WHO experts

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

16 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

In a recent study posted to the bioRxiv* preprint server, researchers at the U.S National Institutes of Health demonstrated the efficacy of molnupiravir and nirmatrelvir, two oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals in the rhesus macaque model, the closest proxy to humans.

7 Sep 2022

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

Dolutegravir-based antiretroviral therapies (ART) for HIV-1 are more effective for pregnant people than some other ART regimens commonly used in the U.S. and Europe, according to a study led by Harvard T.H. Chan School of Public Health researchers.

1 Sep 2022

Immunosuppressive therapies for COVID-19 treatment

In a new study, researchers assessed the impact of baricitinib, netakimab, and tocilizumab against coronavirus disease 2019 (COVID-19).

31 Aug 2022

Relapse of COVID-19 symptoms and SARS-CoV-2 viral load following nirmatrelvir/ritonavir treatment

Researchers reported rapid relapse of COVID-19 symptoms following the administration of nirmatrelvir/ritonavir in adults.

30 Aug 2022

The clinical and virological outcomes associated with molnupiravir or nirmatrelvir–ritonavir use in hospitalized patients with mild-to-moderate COVID-19

Researchers investigated whether early treatment with oral antivirals prevented all-cause mortality in hospitalized patients infected with SARS-CoV-2 new variant of concern Omicron BA.2 subvariant.

29 Aug 2022

Ritonavir News and Research

What is the real-world efficacy of oral antivirals against the SARS-CoV-2 Omicron variant?

Observational study explores the real-world efficacy of oral antivirals against the SARS-CoV-2 Omicron variant

Molnupiravir and nirmatrelvir-ritonavir treatments are effective in reducing mortality among high-risk COVID-19 patients

Are men or women impacted more by adverse reactions to prescription drug treatments?

What is the association of SARS-CoV-2 vaccination with the risk of PASC in patients with SARDs?

Chronic liver disease in COVID-19 patients

Acute kidney injury in hospitalized COVID-19 patients

Impaired immune responses not responsible for COVID-19 rebound, findings suggest

Study finds remdesivir-resistant version of COVID-19 in renal transplant recipients

Antibody drugs are not recommended for patients with covid-19, say WHO experts

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

Immunosuppressive therapies for COVID-19 treatment

Relapse of COVID-19 symptoms and SARS-CoV-2 viral load following nirmatrelvir/ritonavir treatment

The clinical and virological outcomes associated with molnupiravir or nirmatrelvir–ritonavir use in hospitalized patients with mild-to-moderate COVID-19

Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19

What is the viral rebound in untreated COVID-19 infections?

To what extent did the COVID-19 booster strategy prevent infections and hospitalizations in US adults?

Everything you need to know about Paxlovid — especially, should you take it?

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News